93 related articles for article (PubMed ID: 21447952)
1. Treatment outcomes of an integrated residential programme for patients with schizophrenia and substance use disorder.
Morrens M; Dewilde B; Sabbe B; Dom G; De Cuyper R; Moggi F
Eur Addict Res; 2011; 17(3):154-63. PubMed ID: 21447952
[TBL] [Abstract][Full Text] [Related]
2. Impact of co-occurring substance use on 6 month outcomes for young people seeking mental health treatment.
Baker KD; Lubman DI; Cosgrave EM; Killackey EJ; Yuen HP; Hides L; Baksheev GN; Buckby JA; Yung AR
Aust N Z J Psychiatry; 2007 Nov; 41(11):896-902. PubMed ID: 17924242
[TBL] [Abstract][Full Text] [Related]
3. [Prospective study of favorable factors in follow-up of drug addicted patients--apropos of 257 patients of the Cassini Center in Paris].
Goeb JL; Coste J; Bigot T; Ferrand I
Encephale; 2000; 26(6):11-20. PubMed ID: 11217533
[TBL] [Abstract][Full Text] [Related]
4. Substance abuse and first-episode schizophrenia-spectrum disorders. The Danish OPUS trial.
Petersen L; Jeppesen P; Thorup A; Ohlenschlaeger J; Krarup G; Ostergård T; Jørgensen P; Nordentoft M
Early Interv Psychiatry; 2007 Feb; 1(1):88-96. PubMed ID: 21352112
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness.
Bellack AS; Bennett ME; Gearon JS; Brown CH; Yang Y
Arch Gen Psychiatry; 2006 Apr; 63(4):426-32. PubMed ID: 16585472
[TBL] [Abstract][Full Text] [Related]
6. Influence of personality disorder features on social functioning in substance-abusing women five years after compulsive residential treatment.
Jansson I; Hesse M; Fridell M
Eur Addict Res; 2009; 15(1):25-31. PubMed ID: 19052460
[TBL] [Abstract][Full Text] [Related]
7. The Dual Diagnosis Capability of Residential Addiction Treatment centres: priorities and confidence to improve capability following a review process.
Matthews H; Kelly PJ; Deane FP
Drug Alcohol Rev; 2011 Mar; 30(2):195-9. PubMed ID: 21355921
[TBL] [Abstract][Full Text] [Related]
8. Psychiatric comorbidity in first episode schizophrenia: a 2 year, longitudinal outcome study.
Sim K; Chua TH; Chan YH; Mahendran R; Chong SA
J Psychiatr Res; 2006 Oct; 40(7):656-63. PubMed ID: 16904688
[TBL] [Abstract][Full Text] [Related]
9. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.
Potvin S; Stip E; Lipp O; Roy MA; Demers MF; Bouchard RH; Gendron A
Am J Drug Alcohol Abuse; 2008; 34(1):75-82. PubMed ID: 18161645
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
[TBL] [Abstract][Full Text] [Related]
11. Behavioral interventions for dual-diagnosis patients.
Goldsmith RJ; Garlapati V
Psychiatr Clin North Am; 2004 Dec; 27(4):709-25. PubMed ID: 15550289
[TBL] [Abstract][Full Text] [Related]
12. Three-year outcomes of long-term patients with co-occurring bipolar and substance use disorders.
Drake RE; Xie H; McHugo GJ; Shumway M
Biol Psychiatry; 2004 Nov; 56(10):749-56. PubMed ID: 15556119
[TBL] [Abstract][Full Text] [Related]
13. Substance abuse and cognitive functioning in schizophrenia.
Addington J; Addington D
J Psychiatry Neurosci; 1997 Mar; 22(2):99-104. PubMed ID: 9074303
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of substance dependence comorbidity in bipolar, schizophrenic and schizoaffective disorders].
Verdoux H; Mury M; Besançon G; Bourgeois M
Encephale; 1996; 22(2):95-101. PubMed ID: 8706627
[TBL] [Abstract][Full Text] [Related]
15. Treatment setting and baseline substance use severity interact to predict patients' outcomes.
Tiet QQ; Ilgen MA; Byrnes HF; Harris AH; Finney JW
Addiction; 2007 Mar; 102(3):432-40. PubMed ID: 17298651
[TBL] [Abstract][Full Text] [Related]
16. Management of schizophrenia with substance use disorders.
Lybrand J; Caroff S
Psychiatr Clin North Am; 2009 Dec; 32(4):821-33. PubMed ID: 19944886
[TBL] [Abstract][Full Text] [Related]
17. Substance abuse and the management of medication nonadherence in schizophrenia.
Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
[TBL] [Abstract][Full Text] [Related]
18. A comparative evaluation of substance abuse treatment IV. The effect of comorbid psychiatric diagnoses on amount of treatment, continuing care, and 1-year outcomes.
Ouimette PC; Gima K; Moos RH; Finney JW
Alcohol Clin Exp Res; 1999 Mar; 23(3):552-7. PubMed ID: 10195832
[TBL] [Abstract][Full Text] [Related]
19. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.
Green AI
J Clin Psychiatry; 2006; 67 Suppl 7():31-5; quiz 36-7. PubMed ID: 16961422
[TBL] [Abstract][Full Text] [Related]
20. Promoting continuing care adherence among substance abusers with co-occurring psychiatric disorders following residential treatment.
DeMarce JM; Lash SJ; Stephens RS; Grambow SC; Burden JL
Addict Behav; 2008 Sep; 33(9):1104-12. PubMed ID: 18573617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
